WuXi Global Forum 2018 (A Celebration of Global Partnerships)
Now in its sixth year, the WuXi Global Forum during the J.P. Morgan Healthcare Conference brings together more than 2,000 industry leaders to promote new thinking on a global stage as we strive to provide transformative models and solutions for patients. During this captivating forum, thought leaders will discuss the rapid advances and changes impacting the industry, from the most disruptive therapeutic interventions to artificial intelligence to the evolving global regulatory landscape.
Date and Time: 3:00-6:00 PM Pacific Standard Time, Jan 9, 2018
Please register here
to join us for a complimentary live global webcast.
Host: Hui Cai
, Forum Chair and Head of Communications, WuXi AppTec
, President and CEO, Biotechnology Innovation Organization (BIO)
3:10-3:20PM OPENING REMARKS
, Chairman and CEO, WuXi AppTec
3:20-4:00PM BETTING ON THE BEST
From Novartis’ revolutionary cancer treatment, to Celgene’s bold pursuit in science, and to Atlas’ launching of big idea companies, industry leaders will share perspectives on pushing the boundaries of innovation, and what’s coming next.
Moderator: Edward Hu
, CFO and CIO, WuXi AppTec
, President of Novartis Institute for Biomedical Research (NIBR)
, President of Research and Early Development, Celgene
, Partner, Atlas Venture
4:00-4:20PM SPOTLIGHT ON CHINA REGULATORY REFORM
China’s Food and Drug Administration has introduced landmark reforms in 2017 to accelerate new drug approval, which are likely to be a game changer for companies that want to bring innovative products to the world’s second-largest pharmaceutical market more quickly.
Moderator: Steve Yang
, EVP, CBO and CSO, WuXi AppTec
A special guest speaker from CDE/CFDA
4:20-5:00PM LAUNCHPAD 2017
The hurdles could not be higher for young companies working on diseases that have taken their toll even amongst the most experienced drug hunters. This panel takes a closer look at four startup all-stars on how they are tackling tough diseases through unique lenses, and launching a new generation of disruptive therapeutic intervention.
Moderator: Kristina Burow
, Managing Director, ARCH Venture Partners
, CEO of Tango Therapeutics; Venture Partner of Third Rock Ventures
, President and CEO, Sangamo Therapeutics
Geoffrey von Maltzahn
, Co-Founder and Chief Innovation Officer, Kaleido Biosciences
, Executive Chairman of Novocure; Managing Director of WFD Ventures
5:00-5:50PM IS THE FUTURE HERE?
Data. Artificial Intelligence. Deep Learning. What do they really mean? How will they change the future of drug discovery and development? How will they change the way we predict, prevent, diagnose, and treat diseases? And, are we ready?
Moderator: David Beier
, Managing Director, Bay City Capital
, Chief Medical Officer, Verily Life Sciences
, General Partner, Andreessen Horowitz
, Priscilla Chan and Mark Zuckerberg Professor and Director, UCSF
, CEO, Karius
, CEO, Insilico Medicine